{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:52:13Z","timestamp":1782921133095,"version":"3.54.5"},"posted":{"date-parts":[[2026,7,1]]},"group-title":"In Review","reference-count":0,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,11]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <italic>Streptococcus pneumoniae<\/italic>\n                  and\n                  <italic>Clostridium perfringens<\/italic>\n                  are major pathogens causing severe respiratory infections and foodborne illnesses, posing critical threats particularly in communal settings. Current countermeasures face significant limitations, including restricted serotype coverage for\n                  <italic>S. pneumoniae<\/italic>\n                  and the lack of approved vaccines for\n                  <italic>C. perfringens<\/italic>\n                  enterotoxin (CPE). Effective vaccines tailored to these pathogens are urgently needed. Promising candidates include pneumococcal surface protein A (PspA) for broad serotype coverage and the C-terminal receptor binding domain of CPE (C-CPE). The novel sublingual vaccine strategy we present here combines a recombinant bivalent fusion protein PspA-C-CPE with\n                  <italic>Alcaligenes<\/italic>\n                  lipid A, a potent mucosal adjuvant. Sublingual administration of this combination vaccine elicited robust and long-lasting protective immunity in mice. This vaccine effectively neutralized circulating CPE to prevent lethal hyperkalemia and promoted the rapid clearance of\n                  <italic>S. pneumoniae<\/italic>\n                  from the lungs after lethal challenge. Furthermore,\n                  <italic>Alcaligenes<\/italic>\n                  lipid A enhanced the production of IgG against both antigens for at least 49 weeks. These findings demonstrate that sublingual administration of PspA-C-CPE and\n                  <italic>Alcaligenes<\/italic>\n                  lipid A can orchestrate simultaneous defense in the mucosal and systemic compartments. This non-invasive vaccine offers immense public health potential for providing enduring comprehensive, concurrent protection against pneumococcal respiratory infections and CPE-associated foodborne illnesses.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10001561\/v1","type":"posted-content","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:27:06Z","timestamp":1782919626000},"source":"Crossref","is-referenced-by-count":0,"title":["Sublingual bivalent vaccination with PspA-C-CPE and Alcaligenes lipid A induces protective immunity against both Streptococcus pneumoniae and Clostridium perfringens"],"prefix":"10.21203","author":[{"given":"Yuki","family":"Hirayama","sequence":"first","affiliation":[{"name":"National Institutes of Biomedical Innovation, Health, and Nutrition (NIBN)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yoshii","sequence":"additional","affiliation":[{"name":"National Institutes of Biomedical Innovation, Health, and Nutrition (NIBN)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"The University of Osaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Iemitsu","sequence":"additional","affiliation":[{"name":"National Institutes of Biomedical Innovation, Health, and Nutrition (NIBN)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Node","sequence":"additional","affiliation":[{"name":"National Institutes of Biomedical Innovation, Health, and Nutrition (NIBN)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kiyono","sequence":"additional","affiliation":[{"name":"Chiba University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuo","family":"Kondoh","sequence":"additional","affiliation":[{"name":"The University of Osaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukase","sequence":"additional","affiliation":[{"name":"The University of Osaka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kunisawa","sequence":"additional","affiliation":[{"name":"National Institutes of Biomedical Innovation, Health, and Nutrition (NIBN)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10001561\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10001561\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:28:03Z","timestamp":1782919683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10001561\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10001561\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,7,1]]},"subtype":"preprint"}}